Best Practice Considerations by The American Society of Transplant and Cellular Therapy: Infection Prevention and Management After Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies
Zainab Shahid(Quaid-i-Azam University), Joshua A. Hill(Infectious Disease Research Institute), Mehdi Hamadani(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Paul A. Carpenter(Fred Hutch Cancer Center), Nirali N. Shah(National Institutes of Health), Lekha Mikkilineni, Sanjeet Dadwal(City Of Hope National Medical Center), Tania Jain(Johns Hopkins University), Gabriela Marón(St. Jude Children's Research Hospital), M. Veronica Dioverti, Genovefa A. Papanicolaou(Memorial Sloan Kettering Cancer Center), Susan K. Seo(Memorial Sloan Kettering Cancer Center), Swetha Kambhampati Thiruvengadam(City Of Hope National Medical Center), Martina Pennisi(University of Milan)
Cited by 78
Related Papers
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy
|Blood|2017|564
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
|Journal of Clinical Oncology|2019|441
Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation
|Biology of Blood and Marrow Transplantation|2015|409